The Road Ahead
What started as a niche tool has now evolved into a powerful therapeutic strategy. SdAbs have already shown promise against a wide array of diseases—including respiratory syncytial virus (RSV), HIV, and emerging infectious threats—by acting like molecular pliers, gripping tightly to hidden targets that larger antibodies simply can't reach.
As the biotech world pivots toward more compact, customizable biologics, single-domain antibodies are poised to lead the charge. They're not just tiny—they're transformational.
Like
Comment
Share
